Vultaggio Vincent 4

What Happened Vincent Vultaggio, listed as PAO and PFO (principal accounting and principal financial officer) at Zentalis Pharmaceuticals (ZNTL), sold a total of 3,096 shares across two transactions. On 2026-02-02 he sold 2,540 shares at $2.55 each for $6,477, and on 2026-02-03 he sold 556 shares at $2.52 each for $1,398 — aggregate proceeds ≈ $7,875. These were sales (not purchases) and appear to be routine rather than a directional bullish purchase.

Key Details

• Transaction dates/prices:
  • 2026-02-02: 2,540 shares @ $2.55 = $6,477 (Sale)
  • 2026-02-03: 556 shares @ $2.52 = $1,398 (Sale)
• Aggregate sold: 3,096 shares for approximately $7,875.
• Type: Listed as open market or private sale (Form 4 codes: S).
• Footnotes:
  • F1: The sale was made automatically by the issuer to cover tax withholding related to vesting/settlement of previously granted RSUs (applies to the tax-withholding sale).
  • F2: The other sale was effected under a prearranged Rule 10b5‑1 trading arrangement.
• Shares owned after transaction: Not provided in the information you supplied.
• Filing: Form 4 filed 2026-02-04 for transactions on 2026-02-02 and 2026-02-03 — appears to be timely.

Context The Feb 2 sale tied to F1 was an automatic sale to satisfy tax withholding for vested restricted stock units — a common administrative transaction that doesn't necessarily indicate a view on the company. The Feb 3 sale was executed under a Rule 10b5‑1 plan, meaning it was preplanned and similarly not necessarily a real‑time signal of sentiment. For retail investors, purchases by insiders typically carry more informational weight than routine sales like tax withholding or prearranged trades.